Abstract:

In the context of the Diagnosis Related Groups (DRGs) system, the orthopedic hospital implemented refined drug control to provide a pharmacological reference for promoting rational clinical drug use. A statistical analysis was conducted on the hospital’s data from January to December 2021 (prior to the implementation of control), focusing on the types of unreasonable prescriptions. A multi-dimensional analysis was also conducted to identify the underlying causes of inappropriate medication practices. Following this, refined drug control measures were introduced, and data from January to December 2022 (post-control) were compared, examining factors such as the average drug cost, drug expenses for the IC29 diagnosis group, and the drug cost ratio. An interrupted time-series analysis was employed to evaluate the effects of these interventions. The results showed that after the implementation of refined drug control in the orthopedic department, significant reductions were observed in the average cost per patient, average drug cost per patient, drug cost ratio, cost consumption index, average length of hospital stay, and allocation ratio (P < 0.05). In particular, the first month of control (January 2022) saw a marked decrease in average drug costs per patient by 1272.90 yuan (P < 0.01), a reduction in the drug cost ratio by 0.98%, and a decline in drug costs for the IC29 diagnosis group by 616.79 yuan (P > 0.05). Moreover, the rate of unreasonable inappropriate prescribing dropped dramatically from 40.48% in 2021 to 3.57% by December 2022. The refined control of drug use within the orthopedic hospital significantly improved the rationality of clinical prescribing practices, reduced the occurrence of adverse drug reactions, and enhanced patient adherence to prescribed treatments. These findings demonstrated considerable clinical value in promoting efficient and safe drug use.

Key words: Refined control of drugs, Average drug cost, Interrupted time series